Importance of early diagnosis of pancreaticobiliary maljunction without biliary dilatation

Table 1 Clinical features of 8 pancreaticobiliary maljunction patients without biliary dilatation or cancer

Case	Age (yr)	Sex	Process leading to ultrasound	Amylase level in bile (IU/L)	Follow-up
1	30	F	Screening for hepatitis A	528 000	Follow-up after 236 mo
2	55	F	Screening for chronic hepatitis C	69 850	Follow-up after 47 mo
3	65	F	Cholangitis with mild acute pancreatitis	17 272	Follow-up after 40 mo
4	41	F	Right hypochondralgia	117 240	Follow-up after 12 mo
5	70	F	Screening for diabetes mellitus	254 900	Follow-up after 3 mo
6	42	M	Diarrhea	185 000	Unknown after 75 mo
7	47	M	Abdominal pain	300 000	Unknown after 18 mo
8	36	M	Abdominal discomfort	672 100	Unknown after 1 mo

Table 2 Histopathological findings of gallbladders from patients with pancreaticobiliary maljunction without biliary dilatation diagnosed based on gallbladder wall thickening on ultrasound

Case	Thickness of the wall (mm)	Mucosal height (mm)	Hyperplastic change	Hypertrophic muscular layer	Subserosal fibrosis	Adenomyomatosis	Gallstone	Ki-67 labeling index (%)	K-ras mutation
1	7	2.4	+a	-	+	-	-	8	GAT (3+)
2	6	1.8	+	-	+	+	-	5	NA
3	3	0.6	-	-	-	-	+	6	-
4	5	2.2	+	+	+	+	-	4	-
5	5	1.7	+	+	+	+	-	5	NA
6	8	1.9	+	+	+	+	-	8	AGT (1+)
7	6	1.4	+	+	+	-	+	9	AGT (2+)
8	25	0.9	+	+	+	+	-	3	-
PBM, %,	7.7 ± 7.0b	1.06 ± 0.7b	88 (7/8)b	63 (5/8)b	88 (7/8)b	63 (5/8)b	25 (2/8)	6.0 ± 2.1b	50 (3/6)a
mean ± SD
Controls, %,	2.0 ± 0.5	0.58 ± 0.24	0 (0/10)	0 (0/10)	0 (0/10)	0 (0/10)	10 (1/10)	1.2 ± 0.3	0 (0/10)
(n = 10),
mean ± SD

PBM: Pancreaticobiliary maljunction; NA: Not amplified.

^aP < 0.05,

^bP < 0.01 vs controls.